Brokers Offer Predictions for Kura Oncology FY2029 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Analysts at Brookline Capital Management issued their FY2029 EPS estimates for shares of Kura Oncology in a report released on Monday, January 6th. Brookline Capital Management analyst L. Cann expects that the company will earn $12.19 per share for the year. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

A number of other equities analysts have also recently commented on KURA. HC Wainwright lifted their target price on Kura Oncology from $32.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, November 21st. Bank of America lowered their price target on Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research report on Friday, November 22nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research report on Monday, December 9th. UBS Group started coverage on shares of Kura Oncology in a report on Thursday, October 24th. They issued a “buy” rating and a $27.00 target price for the company. Finally, Stifel Nicolaus downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating and cut their price target for the company from $26.00 to $19.00 in a report on Monday, October 14th. One analyst has rated the stock with a sell rating, two have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Kura Oncology presently has an average rating of “Moderate Buy” and an average price target of $27.38.

Kura Oncology Trading Down 4.8 %

KURA opened at $7.78 on Thursday. The stock has a 50-day moving average of $12.11 and a 200 day moving average of $17.08. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 12 month low of $7.70 and a 12 month high of $24.17. The firm has a market cap of $605.00 million, a P/E ratio of -3.30 and a beta of 0.81.

Hedge Funds Weigh In On Kura Oncology

A number of hedge funds have recently added to or reduced their stakes in KURA. Bank of New York Mellon Corp boosted its holdings in shares of Kura Oncology by 4.6% in the second quarter. Bank of New York Mellon Corp now owns 255,897 shares of the company’s stock valued at $5,269,000 after purchasing an additional 11,212 shares during the period. Sofinnova Investments Inc. raised its position in Kura Oncology by 64.4% during the 2nd quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock valued at $16,992,000 after purchasing an additional 323,303 shares in the last quarter. Hsbc Holdings PLC raised its position in Kura Oncology by 13.4% during the 2nd quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock valued at $374,000 after purchasing an additional 2,167 shares in the last quarter. HighVista Strategies LLC purchased a new stake in shares of Kura Oncology in the 2nd quarter worth $345,000. Finally, Integral Health Asset Management LLC bought a new position in shares of Kura Oncology during the 2nd quarter worth $2,059,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.